abrdn plc reduced its holdings in Oculis Holding AG (NASDAQ:OCS - Free Report) by 25.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 820,553 shares of the company's stock after selling 279,879 shares during the quarter. abrdn plc owned 2.03% of Oculis worth $10,064,000 at the end of the most recent quarter.
Oculis Price Performance
Shares of OCS stock traded up $0.70 during mid-day trading on Friday, hitting $17.88. 96,039 shares of the stock traded hands, compared to its average volume of 70,665. Oculis Holding AG has a twelve month low of $9.60 and a twelve month high of $17.95. The firm has a market cap of $724.14 million, a price-to-earnings ratio of -9.31 and a beta of -0.18. The company's 50-day simple moving average is $13.50 and its 200-day simple moving average is $12.43. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.27 and a current ratio of 5.27.
Oculis (NASDAQ:OCS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 27th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.13). Oculis had a negative net margin of 7,679.05% and a negative return on equity of 61.33%. The firm had revenue of $0.27 million for the quarter, compared to analyst estimates of $0.28 million. As a group, equities research analysts expect that Oculis Holding AG will post -2.19 earnings per share for the current year.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a "buy" rating and issued a $30.00 target price on shares of Oculis in a research report on Wednesday, October 23rd. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $29.20.
Check Out Our Latest Stock Analysis on OCS
About Oculis
(
Free Report)
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Further Reading
Before you consider Oculis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oculis wasn't on the list.
While Oculis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
